<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2017.00141</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolic Characterization of a Novel ROR&#x003B1; Knockout Mouse Model without Ataxia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Billon</surname> <given-names>Cyrielle</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/417514"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sitaula</surname> <given-names>Sadichha</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Burris</surname> <given-names>Thomas P.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/416230"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Pharmacology and Physiology, Saint Louis University School of Medicine</institution>, <addr-line>St. Louis, MO</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Paul Webb, Houston Methodist Research Institute, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Sana Siddiqui, University of California, San Francisco, United States; Jonathan Janssens, University of Antwerp, Belgium</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Thomas P. Burris, <email>burristp&#x00040;slu.edu</email></corresp>
<fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Molecular and Structural Endocrinology, a section of the journal Frontiers in Endocrinology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>07</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>141</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>02</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>06</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Billon, Sitaula and Burris.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Billon, Sitaula and Burris</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>The retinoic acid receptor-related receptor &#x003B1; (ROR&#x003B1;) is a nuclear receptor that plays an important role in regulation of metabolism and the immune system. Genetic deletion of the receptor yields mice with significant cerebellar developmental issues associated with severe ataxia. Although many metabolic studies have been performed in these models, the impaired locomotor activity of these mice is known to affect their normal mobility and feeding behaviors. This creates some difficulty in interpretation of the role of ROR&#x003B1; in models of metabolic disease where feeding and muscle function is a critical component of the pathophysiology. We generated a mouse with a floxed <italic>Rora</italic> allele that we crossed with a mouse line expressing Cre recombinase under the control of the EIIa promoter to obtain a full body deletion of <italic>Rora</italic>. This cross led to a partial deletion of the <italic>Rora</italic> locus likely due to mosaic expression of the EIIa-Cre transgene. These mice lack any signs of ataxia but display an improved metabolic profile relative to normal WT mice. The mice were resistant to diet- and age-induced metabolic syndrome and exhibited improved glucose tolerance and increased insulin sensitivity. Decreased ROR&#x003B1; expression in the mice was also associated with reduced inflammation in models of metabolic syndrome. These data indicate that suppression of ROR&#x003B1; activity improves metabolic function and reduces inflammation.</p>
</abstract>
<kwd-group>
<kwd>lipids</kwd>
<kwd>carbohydrates</kwd>
<kwd>nuclear receptor</kwd>
<kwd>metabolism</kwd>
<kwd>metabolic disease</kwd>
</kwd-group>
<contract-num rid="cn01">MH092769</contract-num>
<contract-sponsor id="cn01">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="19"/>
<page-count count="10"/>
<word-count count="6076"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>More than two-thirds of American adults are considered to be overweight or obese. Obesity is associated with a range of diseases including diabetes, cardiovascular diseases and several cancers. Obesity is the result of a positive energy balance, a consequence of excess caloric intake relative to calories expended. Energy expenditure is the combination of resting metabolic rate (energy consumed at rest), the thermogenic effect of food (energy utilized to metabolize food consumed), and energy expended during physical activity. When energy expenditure exceeds energy intake, it results in a negative energy balance leading to weight loss. The mechanisms underlying the regulation of energy balance are not completely understood, but evidence suggests that complex physiological regulation and genetic predisposition are involved (<xref ref-type="bibr" rid="B1">1</xref>). In addition to behavioral interventions, such as dieting and exercise, various pharmacological strategies are also being examined to reduce obesity focused on reducing caloric intake as well as increasing energy expenditure.</p>
<p>Nuclear receptors (NRs) are ligand-dependent transcription factors that regulate many biological functions including development, metabolism, and inflammation (<xref ref-type="bibr" rid="B2">2</xref>). In the context of metabolism, NRs control lipid and glucose homeostasis in a tissue-specific manner. Dysfunction of NR signaling has been shown to be associated with dyslipidemia, insulin resistance, diabetes, obesity, and cardiovascular diseases. Retinoic acid receptor-related orphan receptors (RORs) represent a subfamily of the NRs and are involved in regulation of metabolism and inflammation as well as the pathogenesis of atherosclerosis (<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>). The ROR family is composed of three members: ROR&#x003B1;, ROR&#x003B2;, and ROR&#x003B3;. Both ROR&#x003B1; and ROR&#x003B3; are expressed in immune cells as well as other tissues known to be the key in regulation of metabolic processes in the liver and skeletal muscle (<xref ref-type="bibr" rid="B6">6</xref>). Several studies have implicated ROR&#x003B1; in regulation of glucose and lipid metabolism as well as inflammatory and immune responses <italic>in vivo</italic> using the staggerer (ROR&#x003B1;<sup>sg/sg</sup>) mouse model (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). In staggerer mice, the gene encoding ROR&#x003B1; contains a 6.5&#x02009;kb genomic deletion leading to loss of an exon that encodes part of its ligand-binding domain (LBD). This leads to an exon skip that shifts the reading frame and introduces a premature stop codon, providing a truncated protein lacking the entire LBD that is believed to function as a dominant negative protein. Unfortunately, these mice develop severe ataxia (hence the name &#x0201C;staggerer&#x0201D;) due to a deficit in Purkinje cell development that impairs mobility and normal feeding behavior, making the study of metabolism more complex in this model. The ROR&#x003B1; null mice display an identical phenotype recapitulating the severe ataxia (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>In this study, we describe a new mouse model of deletion of ROR&#x003B1; that does not display ataxia providing an improved model for assessing ROR&#x003B1;-dependent metabolism where &#x0201C;normal&#x0201D; feeding behavior and locomotion are retained. We generated a mouse with a floxed <italic>Rora</italic> allele that we crossed with a mouse line expressing Cre recombinase under the control of the EIIa promoter to obtain a full body deletion of <italic>Rora</italic>. As the EIIa-cre model induced a mosaic expression of the cre recombinase, we did not obtain a total recombination of the <italic>Rora</italic> Flox loci but a partial deletion. These animals (EIIaROR&#x003B1; KO) lack any signs of ataxia but display an improved metabolic profile relative to normal EIIaROR&#x003B1; WT mice. Our study presents a new model to study the role of ROR&#x003B1; in metabolic disorders without the complexity of a cerebellar deficit that may alter normal feeding behavior and physical activity. As ROR&#x003B1; can be targeted by synthetic ligands (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B10">10</xref>), these data suggest that pharmacological modulation of ROR&#x003B1; may be useful to treat metabolic syndrome and related diseases such as diabetes and liver diseases.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2-1">
<title>Animals</title>
<p>All procedures were approved and conducted in accordance to the St. Louis University Institutional Animal Care and Use Committee.</p>
<p>All mice were housed in a 12-h light/dark cycle. At the end of the experiment, mice were euthanized by CO<sub>2</sub> asphyxiation followed by cervical dislocation. Body composition was analyzed weekly by NMR using BioSpin LF50 Body Composition Analyzer (Bruker, Germany). Tissues were collected, snap frozen and stored at &#x02212;80&#x000B0;C for qPCR or western blotting, or fixed in 4% formalin, incubated in 20% sucrose overnight before freezing for cryosection.</p>
</sec>
<sec id="S2-2">
<title>Gene Targeting and Generation of <italic>Rora</italic> Floxed Mice</title>
<p>The floxed ROR&#x003B1; mouse was created by the transgenics core at the Pennington Biomedical Research Center (Baton Rouge, LA, USA) by inserting LoxP sites by homologous recombination flanking the exon three of the <italic>rora</italic> gene. Female <italic>Rora</italic><sup>flox/flox</sup> mice were bred with male mice homozygous for the Cre recombinase gene under the control of the adenovirus EIIA promoter to generate the <italic>Rora</italic><sup>&#x0002B;</sup>/&#x00394;Cre F1 generation. EIIa-Cre transgenic mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA; stock number: 003724). Genotypes were determined by PCR using the oligonucleotide primers: primer 1: 5&#x02032;-GCCCCCTTTCCCGCCAGTAGCTG-3&#x02032;; primer 2: 5&#x02032;-GACCCAGATCCCCTAATAACG-3&#x02032;; primer 3: 5&#x02032;-GCCCTCAAGAAGAGGCTGCAATTT-3&#x02032; (Figure <xref ref-type="fig" rid="F1">1</xref>A).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>ROR&#x003B1; flox loci construct and validation of ROR&#x003B1; deletion. <bold>(A)</bold> Schematic representation of the LoxP sequence in ROR&#x003B1; loci and primer localization. To assess the presence of the LoxP sites and the deleted allele after action of the cre recombinase, two sets of primers were designed (1&#x02013;2 and 1&#x02013;3). 1.5%-Agarose gel representing the genotyping results after PCR amplification. The WT and Flox alleles were amplified with the set of primer 1&#x02013;3, and the deleted allele was amplified with the set of primers 1&#x02013;3. <bold>(B)</bold> White adipose tissue (WAT), liver, brain, brown adipose tissue (BAT), and muscle gene expression for ROR&#x003B1; from 2-month-old EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) (&#x0002A;&#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001).</p></caption>
<graphic xlink:href="fendo-08-00141-g001.tif"/>
</fig>
</sec>
<sec id="S2-3">
<title>Indirect Calorimetry</title>
<p>Respiratory exchange ratio (RER), VO<sub>2</sub>, VCO<sub>2</sub>, heat production, and activity were measured using a monitoring system (Oxymax Comprehensive Lab Animal System; Columbus Instruments, Columbus, OH, USA). Eight aged-matched male mice (EIIaROR&#x003B1; WT and EIIaROR&#x003B1; KO) were housed individually in metabolic cages on a 12&#x02009;h day&#x02013;night cycle, fed with either a normal chow or high fat diet (HFD) (D12492, Research diet). After a 24-h acclimatization period, data were collected every 16&#x02009;min over a 5-day period. The hourly or average values during light and dark periods were calculated. Two-way ANOVA followed by Bonferroni posttest was used to calculate the <italic>p</italic> value.</p>
</sec>
<sec id="S2-4">
<title>Glucose and Insulin Tolerance Test (ITT)</title>
<p>After 6-h fast, EIIaROR&#x003B1; WT and EIIaROR&#x003B1; KO (<italic>n</italic>&#x02009;&#x0003D;&#x02009;8) were injected intraperitoneally with glucose (2&#x02009;g/kg of fat free mass) or insulin (0.75&#x02009;U/kg of fat free mass) (Sigma-Aldrich, St. Louis, MO, USA) to examine glucose tolerance test or ITT, respectively. Blood glucose was measured before the injection (<italic>t</italic>&#x02009;&#x0003D;&#x02009;0&#x02009;min), 15, 30, 60, and 120&#x02009;min after injection using OneTouch Ultra<sup>&#x000AE;</sup>2 glucometer. Blood was collected by tail snip; the first drop was wiped out, and the second drop was used to quantify glucose level.</p>
</sec>
<sec id="S2-5">
<title>Plasma Lipid, Liver Enzyme, and Cytokines Analysis</title>
<p>Mice were euthanized, and blood was collected <italic>via</italic> cardiac puncture. Concentration of plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, triglyceride, and liver enzymes were assessed using Rx Daytona clinical chemistry analyzer (Randox). Plasma TNF&#x003B1; or IL-1&#x003B2; concentrations were detected by ELISA (Mouse TNF alpha ELISA KIT, EMD Millipore and Mouse IL-1 beta Quantikine SixPak, R&#x00026;D Systems, respectively) according to the manufacturer&#x02019;s recommendations.</p>
</sec>
<sec id="S2-6">
<title>Quantitative Real-time PCR</title>
<p>Total RNA was isolated from mouse tissues using PureLink RNA mini kit (Ambion, Life Technologies). RNA was reverse transcribed to make cDNA using qScript&#x02122; cDNA Synthesis Kit (Quanta biosciences) according to the manufacturer&#x02019;s instructions. Real-time PCR was performed using a SYBR-green PCR master mix kit (SYBR SELECT MASTER MIX, Life Technologies). Primers were purchased from Integrated DNA Technologies (see Table S1 in Supplementary Material for sequences).</p>
</sec>
<sec id="S2-7">
<title>Flow Cytometry</title>
<p>Spleens and lymph nodes were harvested into a tissue culture dish and teased apart into a single cell suspension. Cell suspension was passed through a cell 0.22&#x02009;&#x000B5;M filter (EMD Millipore) and centrifuged (300&#x02013;400&#x02009;&#x000D7;&#x02009;<italic>g</italic>) at 4&#x000B0;C. Cell pellet was resuspended in Flow Cytometry Staining Buffer (BioLegend, San Diego, CA, USA) at the final concentration of 2&#x02009;&#x000D7;&#x02009;10<sup>7</sup>&#x02009;cells/mL. Cell surface and intracellular staining were performed according BioLegend protocol (BioLegend). Antibodies used for analysis are listed in Table S2 in Supplementary Material.</p>
</sec>
<sec id="S2-8">
<title>Statistical Analysis</title>
<p>Data are expressed as mean&#x02009;&#x000B1;&#x02009;SEM. Student&#x02019;s <italic>t</italic>-test or two-way ANOVA was used to calculate statistical significance. <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05 was considered significant.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3-1">
<title>EIIaROR&#x003B1; KO Mice Do Not Display a Staggerer Phenotype</title>
<p>Previous studies have shown that homozygous staggerer mice are leaner and display improved insulin sensitivity but also have a severe cerebellar ataxia (<xref ref-type="bibr" rid="B9">9</xref>). To help normalize feeding, these ataxic mice are typically provided food on the bottom of the cage so as to provide more ready access given their locomotor deficits (<xref ref-type="bibr" rid="B9">9</xref>). We generated mice heterozygous for a transgene encoding Cre recombinase expressed under the direction of the EIIa promoter (EIIa-Cre), which directs expression in all tissues, and homozygous for <italic>lox</italic>P-flanked exon 3 of <italic>Rora</italic> gene [Figure <xref ref-type="fig" rid="F1">1</xref>A, <italic>Rora</italic><sup>flox/flox</sup>Cre<sup>&#x0002B;/WT</sup> (EIIaROR&#x003B1; KO)]. <italic>Rora</italic><sup>flox/flox</sup> littermates without the EIIa-Cre transgene (EIIaROR&#x003B1; WT) served as controls. When we assessed the level of <italic>Rora</italic> expression in different tissues, we found that the deletion was not complete. <italic>Rora</italic> expression ranged from 45 to 30% of normal levels depending on the tissue examined. We observed a significant decrease of expression in several tissues: 65% in white adipose tissue (WAT), 65% in liver, 70% in brain, 55% in BAT, and 60% in the skeletal muscle (Figure <xref ref-type="fig" rid="F1">1</xref>B). The EllaROR&#x003B1; KO mice displayed normal locomotion (Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref> in Supplementary Material, activity data at 3-month old) and exhibited no signs of ataxia, from weaning time (day 21) to 15&#x02009;months of age (data not shown). The residual ROR&#x003B1; expression in the brain may explain why the EIIaROR&#x003B1; KO mice do not display ataxia. Overall, no differences in the size or the weight of several organs (liver, kidney, spleen, quadriceps, brown or WATs, heart) were observed (data not shown). There were no gross alterations in brain morphology, but fine characterization of brain morphology and function will be examined in later studies.</p>
</sec>
<sec id="S3-2">
<title>EIIaROR&#x003B1; KO Mice Preferentially Use Fat for Energy</title>
<p>Three-month-old male mice (EIIaROR&#x003B1; KO or EIIaROR&#x003B1; WT) were fed with a chow diet and used to decipher the role of ROR&#x003B1; in energy and glucose metabolism. Whole body composition was determined weekly using NMR (BioSpin LF50, Bruker Germany), and no significant differences were observed in body weight, lean mass, or fat mass (Figure <xref ref-type="fig" rid="F2">2</xref>A). Using indirect calorimetry, we were able to determine that deletion of ROR&#x003B1; leads to an increase in fat oxidation during both day- and nighttime (Figures <xref ref-type="fig" rid="F2">2</xref>C,D). No changes in carbohydrate consumption were observed, but we observed an increase in the total quantity of fat oxidized. This increase of fat utilization led to an increase in energy expenditure with neither an increase in food intake nor activity (Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref> in Supplementary Material). Typically, an RER of 0.7 indicates that mice are fasted and a difference of 0.05 in the RER reflects a change of 20% of fuel utilization. Fat oxidation was increased by 20% in EIIaROR&#x003B1; KO compared to EIIaROR&#x003B1; WT mice when fed a normal chow diet. No differences were observed in levels of blood triglycerides, total cholesterol, HDL, or blood glucose in fasted or fed mice (Figure <xref ref-type="fig" rid="F2">2</xref>B). ROR&#x003B1; deletion did not alter glucose or insulin tolerance (Figure <xref ref-type="fig" rid="F2">2</xref>E). Expression of several lipogenic and cholesterologenic enzyme genes in liver was also unaffected by ROR&#x003B1; deletion (Figure <xref ref-type="fig" rid="F2">2</xref>F). Interestingly, Akt signaling was affected by ROR&#x003B1; deletion. All Akt isoforms (Akt1, 2, and 3) were upregulated in EIIaROR&#x003B1; KO compared to EIIaROR&#x003B1; WT mice (Figure <xref ref-type="fig" rid="F2">2</xref>G). These results demonstrate that ROR&#x003B1; deletion leads to an increase in fat utilization when mice are fed a normal chow diet, but loss of ROR&#x003B1; has no effect on glucose utilization or hepatic cholesterol synthesis.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>EIIAROR&#x003B1; KO mice display an increase fatty acid oxidation and energy expenditure. <bold>(A)</bold> Body composition of single-housed 12-week-old males EIIAROR&#x003B1; WT (<italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (<italic>n</italic>&#x02009;&#x0003D;&#x02009;8) littermates (left panel) and adiposity of the same animals (right panel) fed with a normal chow diet. <bold>(B)</bold> Blood lipid profile (triglycerides, total cholesterol, and HLD) of the same males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8). <bold>(C)</bold> Respiration exchange ratio and <bold>(D)</bold> heat production of the same EIIAROR&#x003B1; WT (white, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) littermates during day (solid pattern) or night (shaded pattern) over a 5-day period and after 24&#x02009;h acclimation (upper panel). Fatty acid oxidation and carbohydrates consumption of the same males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) calculated over a 5-day period. <bold>(E)</bold> Glucose (left) and insulin (right) tolerance test from the same males EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8). Area under the curve is represented on each graph. <bold>(F)</bold> Liver and <bold>(G)</bold> muscle gene expression from the same males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) (&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;&#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.0001).</p></caption>
<graphic xlink:href="fendo-08-00141-g002.tif"/>
</fig>
</sec>
<sec id="S3-3">
<title>EIIaROR&#x003B1; KO Mice Are Resistant to Diet-Induced Obesity (DIO)</title>
<p>Three-month-old male mice were challenged with an HFD (60% calories from fat, Harland TD06414) over 14&#x02009;weeks and monitored for body composition weekly, fuel utilization (at week 1 of HFD) and glucose metabolism. EIIaROR&#x003B1; KO mice exhibited resistance to DIO displaying significantly reduced body weight gain and reduced fat mass relative to control mice (Figure <xref ref-type="fig" rid="F3">3</xref>A). After 7&#x02009;weeks on an HFD, a significant difference in body weight was observed (Figure <xref ref-type="fig" rid="F3">3</xref>A, left panel) and, surprisingly, after only 2&#x02009;weeks on an HFD, fat mass was lower in EIIaROR&#x003B1; KO mice compared to EIIaROR&#x003B1; WT animals (Figure <xref ref-type="fig" rid="F3">3</xref>A, right panel). Three-month-old mice were maintained in the metabolic chambers for 2&#x02009;days on a regular chow diet and then challenged with the same HFD. Metabolic parameters such as RER, oxygen consumption, activity, and energy expenditure were monitored for 5&#x02009;days. After transition to the HFD, the RER displayed a less pronounced circadian pattern of oscillations (Figure <xref ref-type="fig" rid="F3">3</xref>B). During both day- and nighttime, the RER of EIIaROR&#x003B1; KO animals was lower than the wild-type counterparts (Figure <xref ref-type="fig" rid="F3">3</xref>B) consistent with an increase in fatty acid oxidation in the KO mice. We calculated the amount of fatty acid oxidized per hour per kilogram of mouse using the Frayn&#x02019;s equation (<xref ref-type="bibr" rid="B11">11</xref>). We observed 13.5% increase in the quantity of fatty acid oxidized in the EIIaROR&#x003B1; KO animals compared to control mice (Figure <xref ref-type="fig" rid="F3">3</xref>C, right panel). No change in carbohydrate oxidation was observed (Figure <xref ref-type="fig" rid="F3">3</xref>C, left panel). These data suggest that EIIAROR&#x003B1; KO mice were resistant to DIO due to an increase of fatty acid oxidation even with food intake remaining constant (Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref> in Supplementary Material).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>EIIAROR&#x003B1; KO mice are resistant to diet-induced obesity. <bold>(A)</bold> Weekly body weight and adiposity of 3-month-old males EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) mice fed with high fat diet (HFD). <bold>(B)</bold> Fatty acid oxidation (left) and carbohydrates consumption (right) of the same males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) fed with HFD calculated over a 5-day period (&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01, &#x0002A;&#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). <bold>(C)</bold>&#x02009;Indirect calorimetry measurement of the same animals EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) under chow diet and then challenged (black arrow) with HFD (right panel). Average of respiratory exchange ratio (RER) value for day and nighttime of the same EIIAROR&#x003B1; WT (white, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) littermates during day (solid pattern) or night (shaded pattern) over a 5-day period under HFD.</p></caption>
<graphic xlink:href="fendo-08-00141-g003.tif"/>
</fig>
</sec>
<sec id="S3-4">
<title>HFD-Fed ROR&#x003B1; KO Mice Display Improved Glucose Metabolism and an Anti-inflammatory Profile</title>
<p>One side effect of obesity is impaired glucose metabolism, which is associated with insulin resistance and type-2 diabetes. We assessed the effect of ROR&#x003B1; deletion in glucose metabolism in HFD-fed mice for 8&#x02009;weeks. At this time point, a significant difference in body weight and adiposity was observed between EIIAROR&#x003B1; KO mice and their control littermates (Figure <xref ref-type="fig" rid="F3">3</xref>A). As no differences were observed in lean mass and to avoid an effect due to the body weight, we decided to normalize the amount of glucose or insulin injected to lean mass. No difference in response to glucose (Figure <xref ref-type="fig" rid="F4">4</xref>A) was observed between the genotypes, but EIIAROR&#x003B1; KO mice were more sensitive to insulin compared to their EIIAROR&#x003B1; WT littermates (Figure <xref ref-type="fig" rid="F4">4</xref>B). No differences were observed in fasted blood glucose levels between EIIAROR&#x003B1; KO animals and their control littermates (Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref> in Supplementary Material). As obesity is also considered an inflammatory disease, we also assessed the blood levels of pro-inflammatory cytokines IL-1&#x003B2; and TNF&#x003B1;. No differences were observed between the two genotypes with respect to circulating IL-1&#x003B2; level, but we found a significant decrease in circulating TNF&#x003B1; levels in EIIAROR&#x003B1; KO animals compared to EIIAROR&#x003B1; WT mice (Figure <xref ref-type="fig" rid="F4">4</xref>B; Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref> in Supplementary Material). As the WAT can be a source of inflammation, we quantified inflammatory gene expression in this tissue. Most of the pro-inflammatory markers (TNF&#x003B1;, IFN&#x003B3;, CD36, CD11c) displayed a lower level of expression in EIIAROR&#x003B1; KO animals compared to EIIAROR&#x003B1; WT mice (Figures <xref ref-type="fig" rid="F4">4</xref>C,D; Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref> in Supplementary Material). T lymphocytes also play a critical role in WAT-associated inflammation and gene expression for FoxP3, a marker for regulatory T cells (T<sub>reg</sub>), was increased in EIIAROR&#x003B1; KO animals compared to EIIAROR&#x003B1; WT suggesting more infiltration of T<sub>reg</sub> cells (Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref> in Supplementary Material). Previously, we demonstrated that EIIAROR&#x003B1; KO mice display an anti-inflammatory profile with a decrease in CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> cell populations in the spleen when fed a chow diet (<xref ref-type="bibr" rid="B5">5</xref>). These results show that EIIAROR&#x003B1; KO mice display a lower level of inflammation and improved glucose metabolism relative to EIIAROR&#x003B1; WT mice when they are challenged with an HFD. The expression of several genes encoding lipogenic enzymes was analyzed by qPCR, but no differences were observed between EIIAROR&#x003B1; WT and EIIAROR&#x003B1; KO animals (Figure <xref ref-type="fig" rid="F4">4</xref>E). Since EIIAROR&#x003B1; KO mice are more sensitive to insulin, we assessed the role of ROR&#x003B1; deletion in skeletal muscle. The expression of several genes involved in glucose and insulin metabolism was assessed by qPCR, and no major differences were observed between EIIAROR&#x003B1; WT and EIIAROR&#x003B1; KO except for Akt expression (Figure <xref ref-type="fig" rid="F4">4</xref>F).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>EIIAROR&#x003B1; KO mice fed with high fat diet (HFD) display a better glucose homeostasis than EIIAROR&#x003B1; WT mice. <bold>(A)</bold> Glucose and <bold>(B)</bold> insulin tolerance test from the same males EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) used in the Figure <xref ref-type="fig" rid="F3">3</xref>, fed with HFD for 8 and 9&#x02009;weeks, respectively. Area under the curve is represented on each graph. <bold>(C)</bold> Blood TNF&#x003B1; level of the same males EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) fed with HFD for 14&#x02009;weeks quantified by ELISA. <bold>(D)</bold> WAT gene expression from the same males EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) fed with HFD for 14&#x02009;weeks. <bold>(E)</bold> Liver and <bold>(F)</bold> muscle gene expression from the same males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) (&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01).</p></caption>
<graphic xlink:href="fendo-08-00141-g004.tif"/>
</fig>
</sec>
<sec id="S3-5">
<title>Aged-EIIAROR&#x003B1; KO Mice Display Improved Glucose Metabolism and an Anti-inflammatory Profile</title>
<p>Risk for development of metabolic disorders increases with age, thus we decided to study the effect of ROR&#x003B1; deletion in aging. We used 15-month-old male EIIAROR&#x003B1; KO and EIIAROR&#x003B1; WT mice maintained on a normal chow diet. No differences in body composition were observed between the two groups (Figure <xref ref-type="fig" rid="F5">5</xref>A). To determine whether old-EIIAROR&#x003B1; KO mice exhibited increased energy expenditure, we measured activity, heat production, as well as the RER over a 5-day period. No changes were observed in activity, but we observed a decrease in RER suggesting an increase in fat utilization during the resting period (day time) as well as an increase in heat production (Figure <xref ref-type="fig" rid="F5">5</xref>A). These data suggest that EIIAROR&#x003B1; KO mice have a higher rate of energy expenditure and fatty acid oxidation. We also observed that old-EIIAROR&#x003B1; KO mice were more glucose tolerant than old-EIIAROR&#x003B1; WT mice (Figure <xref ref-type="fig" rid="F5">5</xref>B). When we challenged these mice with insulin, old-EIIAROR&#x003B1; KO mice were more sensitive than the WT mice (Figure <xref ref-type="fig" rid="F5">5</xref>B). No differences were observed in fasted blood glucose levels (Figure <xref ref-type="supplementary-material" rid="SM3">S3</xref> in Supplementary Material). Aging is also associated with increased pro-inflammatory cells and cytokines, thus we studied the proportion of different lymphocytes cell populations in the spleens of these mice by flow cytometry. An increase in anti-inflammatory T<sub>H</sub>2 lymphocytes (CD4<sup>&#x0002B;</sup>CD3<sup>&#x0002B;</sup>Gata3<sup>&#x0002B;</sup>) was observed in old-EIIAROR&#x003B1; KO mice compared to old-EIIAROR&#x003B1; WT mice as well as a decrease of pro-inflammatory lymphocytes T<sub>H</sub>17 (CD4<sup>&#x0002B;</sup>CD3<sup>&#x0002B;</sup>IL-17<sup>&#x0002B;</sup>; Figure <xref ref-type="fig" rid="F5">5</xref>C). No changes were observed in number of T<sub>H</sub>1 lymphocytes or T<sub>reg</sub> lymphocytes between the genotypes (Figure <xref ref-type="supplementary-material" rid="SM3">S3</xref> in Supplementary Material). In WAT, a decrease in TNF&#x003B1; expression and an increase the expression of anti-inflammatory genes such as TGF&#x003B2; and macrophage infiltration marker CD36 were observed in old-EIIAROR&#x003B1; KO mice compared to old-EIIAROR&#x003B1; WT mice (Figure <xref ref-type="fig" rid="F5">5</xref>D). These results suggest that deletion of ROR&#x003B1; can be protective in age-induced metabolic disorders such as diabetes and obesity.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>Aged-EIIAROR&#x003B1; KO display improved glucose homeostasis and a lower inflammation rate than EIIAROR&#x003B1; WT mice. <bold>(A)</bold> Body composition of single-housed 15-month-old males EIIAROR&#x003B1; WT (<italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (<italic>n</italic>&#x02009;&#x0003D;&#x02009;7) littermates (left panel) fed with a normal chow diet. Respiration exchange ratio (middle panel) and heat production (right panel) of the same aged-EIIAROR&#x003B1; WT (white, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) littermates during day (solid pattern) or night (shaded pattern) over a 5-day period and after 24&#x02009;h acclimation (upper panel). <bold>(B)</bold> Glucose (upper panel) and insulin (lower panel) tolerance test from the same males aged-EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) fed with a normal chow diet done at 13-month old. Area under the curve is represented on each graph. <bold>(C)</bold> Splenocytes from 15-month-old males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) littermates were analyzed by flow cytometry for T<sub>H</sub>2 [CD3<sup>&#x0002B;</sup>CD4<sup>&#x0002B;</sup>Gata3<sup>&#x0002B;</sup> (upper panel)], or T<sub>H</sub>17 [CD3<sup>&#x0002B;</sup>CD4<sup>&#x0002B;</sup>IL-17<sup>&#x0002B;</sup> (lower panel)]. <bold>(D)</bold> WAT gene expression from the same 15-month-old males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) littermates (&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01, &#x0002A;&#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001, &#x0002A;&#x0002A;&#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.0001).</p></caption>
<graphic xlink:href="fendo-08-00141-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we have described a novel mouse model that we used to characterize the role of ROR&#x003B1; in metabolic disorders. These EIIAROR&#x003B1; KO mice, which expressed significantly reduced ROR&#x003B1; expression relative to WT mice but did not display mobility/ataxia issues typically associated with loss of ROR&#x003B1; function, were protected against diet- and age-induced metabolic syndrome. In these mice, reduction of ROR&#x003B1; expression protected against DIO and improved glucose metabolism and insulin resistance were observed while also decreasing markers of inflammation. Our study extends previous ones utilizing the staggerer mouse model that also suggest a metabolic benefic of ROR&#x003B1; deletion (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). However, metabolic studies in the staggerer mouse have typically been difficult to interpret due to significant developmental abnormalities in these mice leading to cerebellar ataxia. Interestingly, our new mouse model that exhibits a partial deletion of ROR&#x003B1; lacks the troublesome ataxia that leads to abnormal movement and feeding, but we were still able to clearly link lower ROR&#x003B1; activity to improved glucose metabolism, reduced insulin resistance, resistance to diet- or age-induced obesity, and reduced inflammation. These mice also display increased energy expenditure and increased fatty acid oxidation and a reduction in fat mass when maintained on a normal chow diet or an HF diet. Obesity is associated with mild systemic inflammation and that inflammation plays a critical role in pathologies associated to obesity like cardiovascular diseases as well as diabetes. Our study has shown a correlation between level of expression of ROR&#x003B1;, inflammation, and resistance to diet- and age-induced obesity. Infiltration of immune cells, macrophages and T lymphocytes, in WAT leads to production of systemic pro-inflammatory cytokine that trigger the development of systemic inflammation found in obese patients or animal models (<xref ref-type="bibr" rid="B12">12</xref>&#x02013;<xref ref-type="bibr" rid="B14">14</xref>). RORs (ROR&#x003B1; and ROR&#x003B3;) are known to play a role in atherosclerosis and lymphocytes T<sub>H</sub>17 differentiation (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). Our data have shown that a partial deletion of ROR&#x003B1; is sufficient to reduce inflammation and induce T<sub>reg</sub> differentiation and/or proliferation to prevent an increase in inflammation in the WAT. The spleen plays a major role in T cell maturation and activation, and our cytometry study shows an anti-inflammatory profile of T cells in aged-EIIAROR&#x003B1; KO mice. Previously, we showed a similar profile in young EIIAROR&#x003B1; KO mice under chow diet (<xref ref-type="bibr" rid="B5">5</xref>). All these data support the pro-inflammatory role of ROR&#x003B1;, and modulation of its activity can protect against pathological inflammation. One of the key factors controlling T cell fate is the transcription factor hypoxia-inducible factor-1&#x003B1; (HIF-1&#x003B1;). HIF-1&#x003B1; is activated by the level of oxygen and can be regulated by the NF-&#x003BA;B signaling pathway in T cells. Activation of HIF-1&#x003B1; will induced a metabolic switch in cells, which dramatically influences T cell lineage commitment (<xref ref-type="bibr" rid="B15">15</xref>). HIF-1&#x003B1; can attenuate T<sub>reg</sub> differentiation toward T<sub>H</sub>17. Interestingly, HIF-1&#x003B1; has been shown to by directly regulated by ROR&#x003B1; (<xref ref-type="bibr" rid="B16">16</xref>). We hypothesized that the deletion of ROR&#x003B1; can lead to a decrease of HIF-1&#x003B1; expression in na&#x000EF;ve T cells (CD4<sup>&#x0002B;</sup>) that will promote T<sub>reg</sub> differentiation and block T<sub>H</sub>17 differentiation.</p>
<p>Aged-EIIAROR&#x003B1; KO or EIIAROR&#x003B1; KO mice under HF diet for weeks are still insulin sensitive and glucose tolerant, suggesting that these mice are less susceptible to aged or diet-induced type-2 diabetes. Very interestingly, we observed an upregulation of Akt signaling in the muscle of EIIAROR&#x003B1; KO animals, which could explain the more efficient insulin signaling. Further studies regarding the insulin pathway will be necessary to understand the role of ROR&#x003B1; deletion in this process. The mechanisms underlying these results are not clear, but it could be a link to a decrease of inflammation and a better peripheral glucose metabolism. The muscles play a critical role in glucose metabolism and insulin sensitivity (<xref ref-type="bibr" rid="B17">17</xref>). Previous data obtained in the lab have shown that targeting ROR&#x003B1; and ROR&#x003B3; with synthetic inverse agonist reduces diabetes in a non-obese mouse model (<xref ref-type="bibr" rid="B18">18</xref>). The role of each ROR isotype is poorly understood in these mechanisms. Our model will allow us to also study the role of ROR&#x003B1; in specific tissues such as muscle and pancreas and its impact in glucose metabolism and insulin sensitivity.</p>
<p>Obesity and fat accumulation are the results of imbalance between energy intake and expenditure. Indirect calorimetry analysis of 2-month-old EIIAROR&#x003B1; KO and EIIAROR&#x003B1; WT fed with normal chow diet as well as aged EIIAROR&#x003B1; KO and EIIAROR&#x003B1; WT have shown an increase in energy expenditure and fatty acid oxidation without alteration of food intake during both night- and daytime. We hypothesized that the increase in energy expenditure was linked to an increase in thermogenesis in the brown adipose tissue (BAT). To test this, we challenged young EIIAROR&#x003B1; KO and EIIAROR&#x003B1; WT to cold temperature, but no differences were observed in energy expenditure, fatty acid oxidation, or BAT activity (data not shown). We then challenged EIIAROR&#x003B1; KO and EIIAROR&#x003B1; WT mice with HF diet for 8&#x02009;weeks before performing the same indirect calorimetry analysis. As EIIAROR&#x003B1; KO mice accumulate less fat, the normalization to the fat free mass excludes any weight effect in energy expenditure. EIIAROR&#x003B1; KO mice are utilizing more energy during both day- and nighttime and have an increase in fatty acid oxidation. Fatty acid oxidation has been shown to be impaired in aging animals (<xref ref-type="bibr" rid="B19">19</xref>), but our aged-EIIAROR&#x003B1; KO still display an increase in fatty acid oxidation. These results lead to the hypothesis that ROR&#x003B1; may regulate fatty acid oxidation and prevent against aged-dependent decrease of metabolism. The elevated energy expenditure and fatty acid oxidation observed in all our models might explain the reduced fat accumulation and insulin resistance in EIIAROR&#x003B1; KO mice.</p>
<p>In conclusion, we developed a new ROR&#x003B1; deficiency mouse model that recapitulates the observations performed in the Staggerer mice but without the problematic effects of ataxia. Partial deletion of ROR&#x003B1; protects against diet- and age-induced metabolic syndromes and inflammation. This ROR&#x003B1; floxed model will provide a new tool to study the role of ROR&#x003B1; in metabolic syndrome. By generating tissue-specific ROR&#x003B1; deletions using this model, we will be able to better understand the role of ROR&#x003B1; in metabolic tissue and some of the problematic cerebellar developmental effects. We previously published that ROR can be targeted by synthetic ligands and protects against inflammation, diabetes, and cardiovascular diseases (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B18">18</xref>), but unfortunately, we have not been able to decipher the specific role of each receptor isotype nor the role of various isotypes within specific tissues with great precision. With this model, we will be able to better understand the role of ROR&#x003B1; versus ROR&#x003B3; in these diseases and utilize this information to develop improved therapeutic strategies to manage and prevent obesity and related pathologies such as cardiovascular diseases and diabetes.</p>
</sec>
<sec id="S5">
<title>Ethics Statement</title>
<p>All animal studies were approved by the SLU IACUC.</p>
</sec>
<sec id="S6" sec-type="author-contributor">
<title>Author Contributions</title>
<p>TB and CB conceptualized the project; wrote and edited the paper. CB and SS performed experiments. All the authors analyzed the data.</p>
</sec>
<sec id="S7">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>This work was supported by the National Institutes of Health (MH092769). The authors thank Dr. Fernanda Ruiz for her critical reading of the manuscript.</p>
</ack>
<sec id="S8" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at <uri xlink:href="http://journal.frontiersin.org/article/10.3389/fendo.2017.00141/full&#x00023;supplementary-material">http://journal.frontiersin.org/article/10.3389/fendo.2017.00141/full&#x00023;supplementary-material</uri>.</p>
<supplementary-material xlink:href="Image_1.tiff" id="SM1" mimetype="applicationn/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Figure S1</label>
<caption><p>Food intake and activity of single-housed EIIAROR&#x003B1; WT and EIIAROR&#x003B1; KO mice. <bold>(A)</bold> Food intake of single-housed 12-week-old males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) littermates under chow diet over a month. <bold>(B)</bold> Recording of single-housed 12-week-old males EIIAROR&#x003B1; WT (white triangle, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) and EIIAROR&#x003B1; KO (black square, <italic>n</italic>&#x02009;&#x0003D;&#x02009;8) littermate activity in metabolic chambers over a 4-day period. Dark shaded represents nighttime. <bold>(C)</bold> Average of daily food intake of single-housed males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) littermates under high fat diet over 14-week period.</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_2.tiff" id="SM2" mimetype="applicationn/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Figure S2</label>
<caption><p>Blood glucose and inflammatory parameters in male EIIAROR&#x003B1; WT and EIIAROR&#x003B1; KO mice under chow diet. <bold>(A)</bold> Fasted blood glucose level from males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) after 10&#x02009;weeks of high fat diet (HFD). <bold>(B)</bold> Blood IL-1b level in the males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) after 14&#x02009;weeks of HFD determined by ELISA. <bold>(C)</bold> WAT gene expression from males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) after 14&#x02009;weeks of HFD (&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05).</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_3.tiff" id="SM3" mimetype="applicationn/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Figure S3</label>
<caption><p><bold>(A)</bold> Fasted blood glucose level from 13-month-old EIIAROR&#x003B1; WT males (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) mice fed with normal chow diet. <bold>(B)</bold> Splenocytes from 15-month-old males EIIAROR&#x003B1; WT (white bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;6) and EIIAROR&#x003B1; KO (black bar, <italic>n</italic>&#x02009;&#x0003D;&#x02009;7) littermates were analyzed by flow cytometry for Th1 [CD3<sup>&#x0002B;</sup>CD4<sup>&#x0002B;</sup>IFN&#x003B3;<sup>&#x0002B;</sup> (left panel)], or regulatory T cells (T<sub>reg</sub>) [CD3<sup>&#x0002B;</sup>CD4<sup>&#x0002B;</sup>FoxP3<sup>&#x0002B;</sup> (right panel)] (&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01, &#x0002A;&#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001).</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Table_1.PDF" id="SM4" mimetype="applicationn/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.PDF" id="SM5" mimetype="applicationn/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>J</given-names></name> <name><surname>Wyatt</surname> <given-names>H</given-names></name></person-group>. <article-title>The myth of healthy obesity</article-title>. <source>Ann Intern Med</source> (<year>2013</year>) <volume>159</volume>:<fpage>789</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.7326/0003-4819-159-11-201312030-00016</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaven</surname> <given-names>S</given-names></name> <name><surname>Tontonoz</surname> <given-names>P</given-names></name></person-group>. <article-title>Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia</article-title>. <source>Annu Rev Med</source> (<year>2006</year>) <volume>57</volume>:<fpage>313</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.med.57.121304.131428</pub-id><pub-id pub-id-type="pmid">16409152</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gigu&#x000E8;re</surname> <given-names>V</given-names></name> <name><surname>Tini</surname> <given-names>M</given-names></name> <name><surname>Flock</surname> <given-names>G</given-names></name> <name><surname>Ong</surname> <given-names>E</given-names></name> <name><surname>Evans</surname> <given-names>RM</given-names></name> <name><surname>Otulakowski</surname> <given-names>G</given-names></name></person-group>. <article-title>Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors</article-title>. <source>Genes Dev</source> (<year>1994</year>) <volume>8</volume>:<fpage>538</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1101/gad.8.5.538</pub-id><pub-id pub-id-type="pmid">7926749</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solt</surname> <given-names>LA</given-names></name> <name><surname>Kumar</surname> <given-names>N</given-names></name> <name><surname>Nuhant</surname> <given-names>P</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <name><surname>Lauer</surname> <given-names>JL</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand</article-title>. <source>Nature</source> (<year>2011</year>) <volume>472</volume>:<fpage>491</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/nature10075</pub-id><pub-id pub-id-type="pmid">21499262</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Billon</surname> <given-names>C</given-names></name> <name><surname>Sitaula</surname> <given-names>S</given-names></name> <name><surname>Burris</surname> <given-names>T</given-names></name></person-group>. <article-title>Inhibition of ROR&#x003B1;/&#x003B3; suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation</article-title>. <source>Mol Metab</source> (<year>2016</year>) <volume>5</volume>:<fpage>997</fpage>&#x02013;<lpage>1005</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmet.2016.07.001</pub-id><pub-id pub-id-type="pmid">27689012</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>HS</given-names></name> <name><surname>Angers</surname> <given-names>M</given-names></name> <name><surname>Beak</surname> <given-names>JY</given-names></name> <name><surname>Wu</surname> <given-names>X</given-names></name> <name><surname>Gimble</surname> <given-names>JM</given-names></name> <name><surname>Wada</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism</article-title>. <source>Physiol Genomics</source> (<year>2007</year>) <volume>31</volume>:<fpage>281</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1152/physiolgenomics.00098.2007</pub-id><pub-id pub-id-type="pmid">17666523</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>HS</given-names></name> <name><surname>Okamoto</surname> <given-names>K</given-names></name> <name><surname>Takeda</surname> <given-names>Y</given-names></name> <name><surname>Beak</surname> <given-names>JY</given-names></name> <name><surname>Gerrish</surname> <given-names>K</given-names></name> <name><surname>Bortner</surname> <given-names>CD</given-names></name> <etal/></person-group> <article-title>Transcriptional profiling reveals a role for RORalpha in regulating gene expression in obesity-associated inflammation and hepatic steatosis</article-title>. <source>Physiol Genomics</source> (<year>2011</year>) <volume>43</volume>:<fpage>818</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1152/physiolgenomics.00206.2010</pub-id><pub-id pub-id-type="pmid">21540300</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname> <given-names>P</given-names></name> <name><surname>Fitzsimmons</surname> <given-names>RL</given-names></name> <name><surname>Pearen</surname> <given-names>MA</given-names></name> <name><surname>Watt</surname> <given-names>MJ</given-names></name> <name><surname>Muscat</surname> <given-names>GE</given-names></name></person-group>. <article-title>Homozygous staggerer (sg/sg) mice display improved insulin sensitivity and enhanced glucose uptake in skeletal muscle</article-title>. <source>Diabetologia</source> (<year>2011</year>) <volume>54</volume>:<fpage>1169</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-011-2046-3</pub-id><pub-id pub-id-type="pmid">21279323</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dussault</surname> <given-names>I</given-names></name> <name><surname>Fawcett</surname> <given-names>D</given-names></name> <name><surname>Matthyssen</surname> <given-names>A</given-names></name> <name><surname>Bader</surname> <given-names>J-A</given-names></name> <name><surname>Gigu&#x000E8;re</surname> <given-names>V</given-names></name></person-group>. <article-title>Orphan nuclear receptor ROR&#x003B1;-deficient mice display the cerebellar defects of staggerer</article-title>. <source>Mech Dev</source> (<year>1998</year>) <volume>70</volume>:<fpage>147</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/S0925-4773(97)00187-1</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>N</given-names></name> <name><surname>Lyda</surname> <given-names>B</given-names></name> <name><surname>Chang</surname> <given-names>MR</given-names></name> <name><surname>Lauer</surname> <given-names>JL</given-names></name> <name><surname>Solt</surname> <given-names>LA</given-names></name> <name><surname>Burris</surname> <given-names>TP</given-names></name> <etal/></person-group> <article-title>Identification of SR2211: a potent synthetic ROR&#x003B3; selective modulator</article-title>. <source>ACS Chem Biol</source> (<year>2012</year>) <volume>7</volume>:<fpage>672</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1021/cb200496y</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frayn</surname> <given-names>K</given-names></name></person-group>. <article-title>Calculation of substrate oxidation rates in vivo from gaseous exchange</article-title>. <source>J Appl Physiol Respir Environ Exerc Physiol</source> (<year>1983</year>) <volume>55</volume>:<fpage>628</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">6618956</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feuerer</surname> <given-names>M</given-names></name> <name><surname>Herrero</surname> <given-names>L</given-names></name> <name><surname>Cipolletta</surname> <given-names>D</given-names></name> <name><surname>Naaz</surname> <given-names>A</given-names></name> <name><surname>Wong</surname> <given-names>J</given-names></name> <name><surname>Nayer</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters</article-title>. <source>Nat Med</source> (<year>2009</year>) <volume>15</volume>:<fpage>930</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nm.2002</pub-id><pub-id pub-id-type="pmid">19633656</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bastard</surname> <given-names>JP</given-names></name> <name><surname>Maachi</surname> <given-names>M</given-names></name> <name><surname>Lagathu</surname> <given-names>C</given-names></name> <name><surname>Kim</surname> <given-names>MJ</given-names></name> <name><surname>Caron</surname> <given-names>M</given-names></name> <name><surname>Vidal</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Recent advances in the relationship between obesity, inflammation, and insulin resistance</article-title>. <source>Eur Cytokine Netw</source> (<year>2006</year>) <volume>17</volume>:<fpage>4</fpage>&#x02013;<lpage>12</lpage>.</citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McArdle</surname> <given-names>M</given-names></name> <name><surname>Finucane</surname> <given-names>O</given-names></name> <name><surname>Connaughton</surname> <given-names>R</given-names></name> <name><surname>McMorrow</surname> <given-names>A</given-names></name> <name><surname>Roche</surname> <given-names>H</given-names></name></person-group>. <article-title>Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies</article-title>. <source>Front Endocrinol</source> (<year>2013</year>) <volume>4</volume>:<fpage>52</fpage>.<pub-id pub-id-type="doi">10.3389/fendo.2013.00052</pub-id><pub-id pub-id-type="pmid">23675368</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname> <given-names>EV</given-names></name> <name><surname>Barbi</surname> <given-names>J</given-names></name> <name><surname>Yang</surname> <given-names>HY</given-names></name> <name><surname>Jinasena</surname> <given-names>D</given-names></name> <name><surname>Yu</surname> <given-names>H</given-names></name> <name><surname>Zheng</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1</article-title>. <source>Cell</source> (<year>2011</year>) <volume>146</volume>:<fpage>772</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2011.07.033</pub-id><pub-id pub-id-type="pmid">21871655</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>EJ</given-names></name> <name><surname>Yoo</surname> <given-names>YG</given-names></name> <name><surname>Yang</surname> <given-names>WK</given-names></name> <name><surname>Lim</surname> <given-names>YS</given-names></name> <name><surname>Na</surname> <given-names>TY</given-names></name> <name><surname>Lee</surname> <given-names>IK</given-names></name> <etal/></person-group> <article-title>Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia signaling</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2008</year>) <volume>28</volume>:<fpage>1796</fpage>&#x02013;<lpage>802</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.108.171546</pub-id><pub-id pub-id-type="pmid">18658046</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinacore</surname> <given-names>D</given-names></name> <name><surname>Gulve</surname> <given-names>E</given-names></name></person-group>. <article-title>The role of skeletal muscle in glucose transport, glucose homeostasis, and insulin resistance: implications for physical therapy</article-title>. <source>Phys Ther</source> (<year>1993</year>) <volume>73</volume>:<fpage>878</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1093/ptj/73.12.878</pub-id><pub-id pub-id-type="pmid">8248296</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solt</surname> <given-names>L</given-names></name> <name><surname>Banerjee</surname> <given-names>S</given-names></name> <name><surname>Campbell</surname> <given-names>S</given-names></name> <name><surname>Kamenecka</surname> <given-names>T</given-names></name> <name><surname>Burris</surname> <given-names>T</given-names></name></person-group>. <article-title>ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes</article-title>. <source>Endocrinology</source> (<year>2015</year>) <volume>156</volume>:<fpage>869</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1210/en.2014-1677</pub-id><pub-id pub-id-type="pmid">25560829</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname> <given-names>M</given-names></name> <name><surname>Turcotte</surname> <given-names>L</given-names></name></person-group>. <article-title>Impaired fatty acid oxidation in muscle of aging rats perfused under basal conditions</article-title>. <source>Am J Physiol Endocrinol Metab</source> (<year>2002</year>) <volume>282</volume>:<fpage>E1102</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1152/ajpendo.00175.2001</pub-id><pub-id pub-id-type="pmid">11934676</pub-id></citation></ref>
</ref-list>
</back>
</article>